Addax Biosciences is pleased to share the positive outcome of the recent webinar “Discover the Future of Tissue Fixation”, organized in collaboration with CliniSciences Group, which drew significant participation and demonstrated strong interest from the scientific and biomedical community.
The event offered a valuable opportunity to explore advancements in tissue fixation methods, with a particular focus on GAF® (Glyoxal Acid-Free)—an innovative fixative developed by Addax Biosciences as a non-toxic alternative to formalin.
During the webinar, Prof. Giovanni Bussolati, founder and CEO of Addax Biosciences, and Dr. Enrico Berrino, researcher at IRCCS Candiolo, presented the distinctive features of GAF®, highlighting:
-
The absence of formalin, a substance known for its toxicity and carcinogenicity
-
Improved preservation of tissue morphology and molecular integrity
-
Proven diagnostic reliability in oncology applications, including colorectal, lung, and breast cancer
The interest shown by participants and the quality of the scientific discussion confirm the relevance and urgency of this topic in light of the evolving needs of modern pathology and precision medicine.
Addax Biosciences extends its gratitude to CliniSciences Group for their valuable collaboration, and to all professionals who attended and contributed to the exchange with thoughtful questions and observations.